Monitor upcoming clinical data readouts for FHD-909, particularly the Phase 1 monotherapy data expected in 2026, as the strong preclinical results suggest potential for clinical efficacy in SMARCA4-mutant cancers.
Price Chart
Executive Summary
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, including complete tumor regression with FHD-909 in combination with anti-PD1 and strong efficacy in multiple degrader programs. The company also announced its ongoing collaboration with Lilly.
Key Facts
- FHD-909 in combination with anti-PD1 demonstrated complete and durable tumor regression in preclinical models
- Selective CBP degrader FHT-171 showed strong anti-tumor activity in ER+ breast cancer models
- Selective EP300 degrader outperformed clinical benchmark in multiple myeloma models
- Robust degradation achieved with cereblon-based selective ARID1B degraders
- Company has $158.9 million in cash and equivalents as of December 31, 2025
Financial Impact
The company has $158.9 million in cash and equivalents as of December 31, 2025, with $50 million gross proceeds from a January 2026 financing
Risk Factors
- Preclinical results may not translate to human clinical trials
- The company is still in early stages of development with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-026259 |
| Exhibit: exhibit992foghornaacrpress.htm | 0001628280-26-026259 |
| Document: fhtx-20260421.htm | 0001628280-26-026259 |
| Document: 0001628280-26-026259-index-headers.html | 0001628280-26-026259 |
| Document: 0001628280-26-026259-index.html | 0001628280-26-026259 |
| Document: 0001628280-26-026259.txt | 0001628280-26-026259 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $5.57 $4.87 | ▼ −12.57% | ▼ −13.17% | $2.13 (−61.76%) |
May 7, 2026 21w ago | 8-K | $4.20 $3.64 | ▼ −13.33% | ▼ −16.47% | $2.13 (−49.29%) |
Apr 21, 2026 23w ago | Press Release | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.13 (−60.48%) |
Apr 21, 2026 23w ago | 8-K | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.13 (−60.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access